Changes in Hong Kong stocks | Quanxin Biotech (02509) rose more than 9% in early trading, and BD results concentrated on commercializing the first product

The Zhitong Finance App learned that Quanxin Biotech B (02509) rose more than 9% in early trading. As of press release, it rose 5.60% to HK$17.15, with a turnover of HK$26.7093 million.

According to the news, Quanxin Biotech's mid-term financial report shows that the company's BD results are being implemented intensively. Of the 424 million revenue in the first half of the year, the total revenue from the licensing agreement reached 379 million yuan, mainly including down payment and non-cash consideration for TSLP/IL-13 dual antibody QX027N overseas licenses, TSLP monoclonal antibody QX008N milestone payments, and TSLP/IL-33 dual-antibody QX031N milestone payments.

Huachuang Securities pointed out that the “Quanxin 1.0” monoclonal antibody product layout results are gradually showing. Sales of the first commercial product, the usinudan biosimilar drug Xeroxin® /Xygenin® (QX001S), were strong. Its commercial partners recorded domestic sales of more than 300 million yuan in the first half of 2026, surpassing the full year level of last year. The company obtained total product supply and profit sharing revenue of more than 49.5 million yuan; in May, Crohn's disease (CD) indications were approved.